Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ironwood Pharma (IRWD)
NASDAQ:IRWD
IRWD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.59 - $15.26
Previous CloseN/A
Volume359.32K
Average Volume (3M)3.81M
Market Cap
$320.06M
Enterprise Value$1.19B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.77
Next Earnings
May 01, 2025EPS Estimate
0.09Last Dividend Ex-Date
Apr 02, 2019Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding160,028,380
10 Day Avg. Volume6,762,229
30 Day Avg. Volume3,810,524
Standard Deviation0.13
R-Squared0.01
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.85
Price to Cash Flow (P/CF)8.10
P/FCF Ratio8.10
Enterprise Value/Market Cap3.71
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.51
Enterprise Value/Ebitda11.18
Forecast
1Y Price Target
$8.80Price Target Upside363.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Competitive PositioningFDA issued a CRL for competitor ZEAL's short bowel syndrome drug glepaglutide, which is an incremental positive for the positioning of IRWD's SBS candidate apraglutide.
Market DynamicsIRWD stock is expected to trade favorably due to the delay of a potential competitor.
RegulatoryInclusion of new data in Apra NDA submission could be positive for the label.
Bears Say
Financial PerformanceWith $600M in debt and 2025 guidance of >$85M adjusted EBITDA, it is difficult to make the balance sheet math work.
Market OutlookGuidance assumes continued weakness for Linzess beyond Part D redesign dynamics.
Pricing PressureLinzess pricing pressure continues to put incremental pressure on base business.
---
Ownership Overview
13.19% Insiders
18.91% Mutual Funds
33.26% Other Institutional Investors
9.86% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IRWD FAQ
What was Ironwood Pharma’s price range in the past 12 months?
Ironwood Pharma lowest stock price was $1.59 and its highest was $15.26 in the past 12 months.
What is Ironwood Pharma’s market cap?
Ironwood Pharma’s market cap is $320.06M.
When is Ironwood Pharma’s upcoming earnings report date?
Ironwood Pharma’s upcoming earnings report date is May 01, 2025 which is in 69 days.
How were Ironwood Pharma’s earnings last quarter?
Currently, no data Available
Is Ironwood Pharma overvalued?
According to Wall Street analysts Ironwood Pharma’s price is currently Undervalued.
Does Ironwood Pharma pay dividends?
Ironwood Pharma pays a Notavailable dividend of $2.285 which represents an annual dividend yield of N/A. See more information on Ironwood Pharma dividends here
What is Ironwood Pharma’s EPS estimate?
Ironwood Pharma’s EPS estimate is 0.09.
How many shares outstanding does Ironwood Pharma have?
Ironwood Pharma has 160,028,380 shares outstanding.
What happened to Ironwood Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ironwood Pharma?
Currently, no hedge funds are holding shares in IRWD
---
Ironwood Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.80 (363.16% Upside)
$8.80 (363.16% Upside)
Blogger Sentiment
Bearish
IRWD Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 610.0 Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $428.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.8%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.69%
12-Months-Change
Fundamentals
Return on Equity
-8.02%
Trailing 12-Months
Asset Growth
-25.67%
Trailing 12-Months
Company Description
Ironwood Pharma
Ironwood Pharmaceuticals, Inc. is a commercial biotechnology company, which engages in the discovery, commercialization, and development of medicines. Its products include linaclotide, a guanylate cyclase type-C agonists which treats patients irritable bowel syndrome with constipation and chronic constipation. The company was founded by Peter M. Hecht, Eric F. Summers, G. Todd Milne, Brian M. Cali, Joseph C. Cook Jr., and Gina Bornino Miller on January 5, 1998 and is headquartered in Boston, MA.
---
IRWD Company Deck
---
IRWD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted robust prescription growth for LINZESS and significant progress with apraglutide, indicating a strong market position and potential for future growth. However, considerable pricing pressures on LINZESS and program adjustments in the pipeline present notable challenges.Read More>---
IRWD Stock 12 Month Forecast
Average Price Target
$8.80
▲(363.16% Upside)
Technical Analysis
Best Analysts Covering IRWD
1 Year
1 Year Success Rate
0/11 ratings generated profit
1 Year Average Return
-61.37%
reiterated a buy rating 23 days ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -61.37% per trade.
---